Gujarat Themis Biosyn Intrinsic Value
GUJTHEM • Healthcare
Current Stock Price
₹251.31
Primary Intrinsic Value
₹96.80
Market Cap
₹276.4 Cr
+17.2%
Upside
Median Value
₹294.55
Value Range
₹75 - ₹628
Assessment
Trading Below Median Value
Safety Margin
14.7%
GUJTHEM Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹96.80 | ₹77.44 - ₹116.16 | -61.5% | EPS: ₹4.40, Sector P/E: 22x |
| Book Value Method | asset | ₹450.91 | ₹405.82 - ₹496.00 | +79.4% | Book Value/Share: ₹225.45, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹294.55 | ₹265.10 - ₹324.01 | +17.2% | Revenue/Share: ₹147.27, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹502.62 | ₹452.36 - ₹552.88 | +100.0% | EBITDA: ₹75.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹628.27 | ₹502.62 - ₹753.92 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹75.39 | ₹67.85 - ₹82.93 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹75.39 | ₹67.85 - ₹82.93 | -70.0% | Revenue Growth: 8.0%, Adj P/E: 15.6x |
| ROE Based Valuation | profitability | ₹502.62 | ₹452.36 - ₹552.88 | +100.0% | ROE: 19.4%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹149.40 | ₹134.46 - ₹164.34 | -40.6% | EPS: ₹4.40, BVPS: ₹225.45 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
GUJTHEM Intrinsic Value Analysis
What is the intrinsic value of GUJTHEM?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Gujarat Themis Biosyn (GUJTHEM) is ₹294.55 (median value). With the current market price of ₹251.31, this represents a +17.2% variance from our estimated fair value.
The valuation range spans from ₹75.39 to ₹628.27, indicating ₹75.39 - ₹628.27.
Is GUJTHEM undervalued or overvalued?
Based on our multi-method analysis, Gujarat Themis Biosyn (GUJTHEM) appears to be trading below median value by approximately 17.2%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.62 | Industry Standard: 2.0+ | Above 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 19.4% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 45.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.54x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Gujarat Themis Biosyn
Additional stock information and data for GUJTHEM
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹91 Cr | ₹35 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹64 Cr | ₹37 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹40 Cr | ₹30 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹40 Cr | ₹25 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹11 Cr | ₹10 Cr | Positive Free Cash Flow | 8/10 |